Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

SML1457

Sigma-Aldrich

Lonafarnib

≥98% (HPLC)

Sinónimos:

4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, SCH-66336, SCH66336

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C27H31Br2ClN4O2
Número de CAS:
193275-84-2
Peso molecular:
638.82
MDL number:
MFCD06795138
UNSPSC Code:
12352200
PubChem Substance ID:
329825894
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

O=C(N)N(CC1)CCC1CC(N2CCC([C@H]3C(N=CC(Br)=C4)=C4CCC5=C3C(Br)=CC(Cl)=C5)CC2)=O

InChI

1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1

InChI key

DHMTURDWPRKSOA-RUZDIDTESA-N

Gene Information

human ... FNTA(2339) , FNTB(2342)

General description

Lonafarnib (SCH66336) is a farnesyl transferase inhibitor (FTI). K- and N-Ras are substrates of farnesyl transferase.

Biochem/physiol Actions

Lonafarnib is a potent inhibitor of farnesyltransferase, an enzyme responsible for a post-translational modification of proteins (including Ras) that gives a protein sufficient hydrophobicity to translocate to the plasma membrane. Farnesylation regulates signaling cascades controlling cell survival, proliferation and differentiation, so variety of possible uses is not surprising a post-translational modification of proteins (including Ras) that gives a protein sufficient hydrophobicity to translocate to the plasma membrane. Lonafarnib has been studies for possible treatment of progeria, various cancers, and hepatitis D.
Lonafarnib prevents the post-translational lipid modification of H-Ras and other farnesylated proteins. Lonafarnib treatment results in microtubule bundling, increased microtubule acetylation and stabilization and suppression of microtubule dynamics.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI, et al.
Cancer Research, 65(9), 3883-3893 (2005)
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso A D, et al.
The Journal of Biological Chemistry, 280(35), 31101-31108 (2005)
Oren Yakovian et al.
iScience, 25(11), 105282-105282 (2022-10-29)
NRas is a key mediator of the mitogenic pathway in normal cells and in cancer cells. Its dynamics and nanoscale organization at the plasma membrane (PM) facilitate its signaling. Here, we used two-color photoactivated localization microscopy to resolve the organization
Woo-Jin Lim et al.
Cells, 10(9) (2021-09-29)
Retrospective observational studies have reported that statins improve clinical outcomes in patients previously treated with programmed cell death protein 1 (PD-1)-targeting monoclonal antibodies for malignant pleural mesothelioma (MPM) and advanced non-small cell lung cancer (NSCLC). In multiple mouse cancer models
Charlotte Bach et al.
Antiviral research, 209, 105477-105477 (2022-12-14)
Chronic hepatitis D is the most aggressive form of chronic viral hepatitis. It is caused by super-infection of hepatitis B virus (HBV)-infected hepatocytes with hepatitis D virus (HDV). While the recent conditional approval of bulevirtide for HDV treatment offers a
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico